Medical Review (Oct 2024)

Complement factor H in molecular regulation of angiogenesis

  • Li Jiang,
  • Wang Kaili,
  • Starodubtseva Maria N.,
  • Nadyrov Eldar,
  • Kapron Carolyn M.,
  • Hoh Josephine,
  • Liu Ju

DOI
https://doi.org/10.1515/mr-2023-0048
Journal volume & issue
Vol. 4, no. 5
pp. 452 – 466

Abstract

Read online

Angiogenesis, the process of formation of new capillaries from existing blood vessels, is required for multiple physiological and pathological processes. Complement factor H (CFH) is a plasma protein that inhibits the alternative pathway of the complement system. Loss of CFH enhances the alternative pathway and increases complement activation fragments with pro-angiogenic capacity, including complement 3a, complement 5a, and membrane attack complex. CFH protein contains binding sites for C-reactive protein, malondialdehyde, and endothelial heparan sulfates. Dysfunction of CFH prevents its interaction with these molecules and initiates pro-angiogenic events. Mutations in the CFH gene have been found in patients with age-related macular degeneration characterized by choroidal neovascularization. The Cfh-deficient mice show an increase in angiogenesis, which is decreased by administration of recombinant CFH protein. In this review, we summarize the molecular mechanisms of the anti-angiogenic effects of CFH and the regulatory mechanisms of CFH expression. The therapeutic potential of recombinant CFH protein in angiogenesis-related diseases has also been discussed.

Keywords